$ News

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen

AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

HC Wainwright & Co. Downgrades AtaiBeckley to Neutral, Lowers Price Target to $7.5

Guggenheim Downgrades AtaiBeckley to Neutral

Jefferies Downgrades AtaiBeckley to Hold, Lowers Price Target to $7.5

Canaccord Genuity Downgrades AtaiBeckley to Hold, Announces $8 Price Target

Eli Lilly Acquires Psychedelics Specialist AtaiBeckley - What Investors Should Know

Needham Downgrades AtaiBeckley to Hold

Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple

Is AtaiBeckley Inc. (ATAI) Stock a Psychedelic Medicine Opportunity Ahead of Phase 2 Results?

Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year?

Canaccord Genuity Maintains Buy on AtaiBeckley, Raises Price Target to $17

Jefferies Maintains Buy on AtaiBeckley, Maintains $10 Price Target

AtaiBeckley Completes Patient Dosing In Depression Drug Trial, Expects Depression Treatment Trial Data In Late 2026

AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish